The news last month that IBM would stop selling Watson for Drug Discovery due to lackluster financial returns did not come as a surprise to some executives in the field of artificial intelligence-led drug discovery and development. But, they said, that doesn’t mean the field as a whole is in trouble. For one such company, Recursion Pharma, the news did not come as a major surprise. “A key distinction is between analysis of data sets via AI that is prospective versus retrospective.” says  Recursion CEO Christopher Gibson. For AI to work, Gibson says, data sets need to be tailored to it. Learn More